Quantum Biopharma (QNTM) Change in Account Payables (2019 - 2026)
Quantum Biopharma recorded quarterly Change in Account Payables of -$3.3 million in Q1 2026, down 1421.9% quarter-over-quarter from -$214343.0 in Q4 2025, and down 238.41% year-over-year from $2.4 million in Q1 2025.
Quantum Biopharma's Change in Account Payables history runs 8 years deep, the most recent figure standing at -$3.3 million for Q1 2026.
- In Q1 2026, Change in Account Payables fell 238.41% year-over-year to -$3.3 million; the TTM figure through Mar 2026 stood at -$1.4 million (down 159.42% YoY), while the FY2025 annual figure was $4.2 million, down 2.07% from the prior year.
- Change in Account Payables came in at -$3.3 million for Q1 2026 at Quantum Biopharma, down from -$214343.0 in the prior quarter.
- In the past five years, Change in Account Payables ranged from a high of $7.7 million in Q1 2023 to a low of -$3.3 million in Q1 2026.
- A 5-year average of $2.9 million and a median of $3.2 million in 2025 frame the typical range for Change in Account Payables.
- Across the five-year window, Change in Account Payables soared 1656.91% in 2023 and slumped 238.41% in 2026, its largest moves.
- Quantum Biopharma's Change in Account Payables stood at $723769.0 in 2022, then decreased by 20.54% to $575080.0 in 2023, then soared by 443.46% to $3.1 million in 2024, then sank by 106.86% to -$214343.0 in 2025, then plunged by 1421.9% to -$3.3 million in 2026.
- According to Business Quant data, Change in Account Payables over the past three periods registered -$3.3 million, -$214343.0, and $4.1 million for Q1 2026, Q4 2025, and Q3 2025 respectively.
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Change in Account Payables (Qtr) |
|---|---|---|---|---|---|
| 1 | Quantum Biopharma | 961,148.99 Bn | 961,148.98 Bn | - | -3.26 Mn |
| 2 | Alterity Therapeutics | 744,933.29 Bn | 744,933.26 Bn | - | - |
| 3 | Legend Biotech | 2,540.00 Bn | 2,539.71 Bn | 242.10 Mn | - |
| 4 | Nanobiotix | 2,199.85 Bn | 2,199.78 Bn | - | - |
| 5 | Akari Therapeutics | 1,635.88 Bn | 1,635.88 Bn | - | - |
| 6 | Vertex Pharmaceuticals | 111.32 Bn | 104.07 Bn | 2.59 Bn | 35.60 Mn |
| 7 | Evaxion A | 62.56 Bn | 62.54 Bn | - | - |
| 8 | Regeneron Pharmaceuticals | 62.55 Bn | 53.79 Bn | 3.31 Bn | - |
| 9 | Alnylam Pharmaceuticals | 39.57 Bn | 36.56 Bn | 959.66 Mn | - |
| 10 | Revolution Medicines | 32.39 Bn | 32.39 Bn | - | 16.86 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | 3.59 Mn |
| Mar 31, 2026 | 3.59 Mn |
| Dec 31, 2025 | -214,343.00 |
| Dec 31, 2025 | -214,343.00 |
| Sep 30, 2025 | 4.09 Mn |
| Sep 30, 2025 | 4.09 Mn |
| Jun 30, 2025 | 3.19 Mn |
| Jun 30, 2025 | 3.19 Mn |
| Mar 31, 2025 | -177,476.00 |
| Mar 31, 2025 | -177,476.00 |
| Dec 31, 2024 | 3.13 Mn |
| Dec 31, 2024 | 3.13 Mn |
| Sep 30, 2024 | 3.31 Mn |
| Sep 30, 2024 | 3.31 Mn |
| Jun 30, 2024 | 4.42 Mn |
| Jun 30, 2024 | 4.42 Mn |
| Mar 31, 2024 | -1.05 Mn |
| Mar 31, 2024 | -1.05 Mn |
| Dec 31, 2023 | 575,080.00 |
| Dec 31, 2023 | 575,080.00 |
| Sep 30, 2023 | 3.70 Mn |
| Sep 30, 2023 | 3.70 Mn |
| Jun 30, 2023 | 5.32 Mn |
| Jun 30, 2023 | 5.32 Mn |
| Mar 31, 2023 | 7.71 Mn |
| Mar 31, 2023 | 7.71 Mn |
| Dec 31, 2022 | 723,769.00 |
| Dec 31, 2022 | 723,769.00 |
| Sep 30, 2022 | 6.49 Mn |
| Sep 30, 2022 | 6.49 Mn |
| Jun 30, 2022 | 7.66 Mn |
| Jun 30, 2022 | 7.66 Mn |
| Mar 31, 2022 | 7.87 Mn |
| Mar 31, 2022 | 7.87 Mn |
| Dec 31, 2021 | 676,145.00 |
| Dec 31, 2021 | 676,145.00 |
| Sep 30, 2021 | 6.69 Mn |
| Sep 30, 2021 | 6.69 Mn |
| Jun 30, 2021 | 7.95 Mn |
| Jun 30, 2021 | 7.95 Mn |
| Mar 31, 2021 | 1.82 Mn |
| Mar 31, 2021 | 1.82 Mn |
| Dec 31, 2020 | 3.70 Mn |
| Dec 31, 2020 | 3.70 Mn |
| Sep 30, 2020 | 2.47 Mn |
| Sep 30, 2020 | 2.47 Mn |
| Jun 30, 2020 | 3.02 Mn |
| Jun 30, 2020 | 3.02 Mn |
| Mar 31, 2020 | -20,302.50 |
| Mar 31, 2020 | -20,302.50 |
| Dec 31, 2019 | 3.38 Mn |
| Dec 31, 2019 | 3.38 Mn |
| Mar 31, 2019 | 24,773.39 |
| Mar 31, 2019 | 24,773.39 |